文献速递乳腺癌

智能真空辅助活检识别新辅助全身治疗后达到病理完全缓解(ypT0且ypN0)的乳腺癌患者以豁免乳腺及腋窝手术

Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
PubMed 文献 · J Clin Oncol · 2022-02-02

本研究训练、测试并验证一种机器学习算法(智能VAB),利用患者、影像、肿瘤及VAB变量,在手术前检测新辅助全身治疗后残留癌(ypT+或原位癌或ypN+)。开发集318例,外部验证集45例,智能VAB的假阴性率为0.0%-5.2%,特异度为37.5%-40.0%,AUC为0.91-0.92。结论认为智能VAB算法可可靠排除残留癌,豁免手术可在未来试验中评估。

要点

  • 智能VAB在开发集和外部验证集中检测残留癌的假阴性率为0.0%-5.2%。
  • 智能VAB特异度为37.5%-40.0%,AUC为0.91-0.92,模型校准良好(Spiegelhalter's Z z评分-0.746,P=.228)。
  • 智能VAB假阴性率低于新辅助全身治疗后影像、单独VAB或两者组合。

核心结论

  • 智能VAB算法可可靠排除新辅助全身治疗后的残留癌。
  • 对于这些 exceptional responders,豁免乳腺及腋窝手术可在未来试验中评估。

研究设计与样本

  • 研究训练、测试并验证一种机器学习算法,使用患者、影像、肿瘤及VAB变量检测新辅助全身治疗后手术前残留癌(ypT+或原位癌或ypN+)。
  • 开发集纳入318例cT1-3、cN0或+、人表皮生长因子受体2阳性、三阴性或高增殖Luminal B样乳腺癌女性,手术前接受VAB(ClinicalTrials.gov标识符NCT02948764,RESPONDER试验)。
  • 采用10折交叉验证训练和测试算法,并使用独立试验数据外部验证(ClinicalTrials.gov标识符NCT02575612),外部验证集n=45。
  • 与手术标本的组织病理学评估进行比较,主要结局为假阴性率和特异度。

主要发现

  • 在开发集(n=318)和外部验证集(n=45)中,智能VAB检测新辅助全身治疗后残留癌(ypT+或原位癌或ypN+)的假阴性率为0.0%-5.2%,特异度为37.5%-40.0%,受试者工作特征曲线下面积为0.91-0.92。
  • Spiegelhalter's Z确认模型校准良好(z评分-0.746,P=.228)。
  • 智能VAB的假阴性率低于新辅助全身治疗后影像、单独VAB或两者组合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in 40%-70% of women with breast cancer. These patients may not need surgery as all local tumor has already been eradicated by NST. However, nonsurgical approaches, including imaging or vacuum-assisted biopsy (VAB), were not able to accurately identify patients without residual cancer in the breast or axilla. We evaluated the feasibility of a machine learning algorithm (intelligent VAB) to identify exceptional responders to NST. METHODS: We trained, tested, and validated a machine learning algorithm using patient, imaging, tumor, and VAB variables to detect residual cancer after NST (ypT+ or in situ or ypN+) before surgery. We used data from 318 women with cT1-3, cN0 or +, human epidermal growth factor receptor 2-positive, triple-negative, or high-proliferative Luminal B-like breast cancer who underwent VAB before surgery (ClinicalTrials.gov identifier: NCT02948764, RESPONDER trial). We used 10-fold cross-validation to train and test the algorithm, which was then externally validated using data of an independent trial (ClinicalTrials.gov identifier: NCT02575612). We compared findings with the histopathologic evaluation of the surgical specimen. We considered false-negative rate (FNR) and specificity to be the main outcomes. RESULTS: In the development set (n = 318) and external validation set (n = 45), the intelligent VAB showed an FNR of 0.0%-5.2%, a specificity of 37.5%-40.0%, and an area under the receiver operating characteristic curve of 0.91-0.92 to detect residual cancer (ypT+ or in situ or ypN+) after NST. Spiegelhalter's Z confirmed a well-calibrated model (z score -0.746, P = .228). FNR of the intelligent VAB was lower compared with imaging after NST, VAB alone, or combinations of both. CONCLUSION: An intelligent VAB algorithm can reliably exclude residual cancer after NST. The omission of breast and axillary surgery for these exceptional responders may be evaluated in future trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pfob A, Sidey-Gibbons C, Rauch G, et al. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. J Clin Oncol. 2022. PMID: 35108029. doi:10.1200/JCO.21.02439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。